Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Tablets 30 X 12.5 mg |
|
42314 | 9658 |
|
Tablets 30 X 6.25 mg |
|
42315 | 9659 |
Related information
Dosage
See prescribing information for full details.
Indications
Treatment of symptomatic congestive heart failure (CHF). May be used as adjunct to standard therapy, but may also be used in those patients unable to tolerate an ACE inhibitor, or those who are not receiving digitalis, hydralazine or nitrate therapy.
Contra-Indications
Patients with marked fluid retention or overload requiring intravenous inotropic support. Patients with obstructive airways disease, liver dysfunction, hypersensitivity to carvedilol or any other constituents of the tablets. As with other beta-blocking agents: History of bronchospasm or asthma, 2nd and 3rd degree AV heart block, severe bradycardia (< 50 bpm), cardiogenic shock, sick sinus syndrome (including sino-atrial block), severe hypotension (systolic blood pressure < 85mmHg), metabolic acidosis and pheochromocytoma (unless adequately controlled by alpha blockade).
Special Precautions
Contact distributing company for full details.
Side Effects
Contact distributing company for full details.
Drug interactions
Contact distributing company for full details.
